P. aeruginosa is an opportunistic pathogen and a leading cause of nosocomial infections, especially in a setting of epithelial cell injury and in immunocompromised patients. P. aeruginosa is also an important pathogen in patients with chronic obstructive pulmonary disorder, bronchiectasis, community acquired pneumonia, ventilator-associated pneumonia and cystic fibrosis. Recent studies suggest that viral and P. aeruginosa infections of the lung are synergistic: however, little is known about the underlying mechanisms whereby P. aeruginosa exacerbates viral infections. Accordingly, the long-term goal of our research is to elucidate the cellular and molecular mechanisms whereby P. aeruginosa causes lung disease and to elucidate the mechanism whereby P. aeruginosa exacerbates viral infections of the lung. Recently, we demonstrated that P. aeruginosa secretes a protein called Cif (CFTR Inhibitory Factor, originally named because of its ability to inhibit CFTR-mediated Cl secretion by airway cells). Cif is secreted by laboratory and clinical isolates of P. aeruginosa and inhibits the host immune response by down-regulating CFTR Cl secretion, which reduces mucociliary clearance, and by reducing the abundance of TAP1 (Transporter Associated with Antigen Presentation), which suppresses vial antigen presentation by class I MHC and the ability of cytotoxic T lymphocytes to clear viral infections. Cif is the first example of a protein secreted by a bacterium that down regulates viral antigen presentation by MHC class I. Preliminary data demonstrate that Cif inhibits the deubiquitination of CFTR and TAP1 in polarized human airway epithelial cells by facilitating G3BP1 inhibition of USP10, a ubiquitin-specific protease, thereby increasing the amount of ubiquitinated, and degraded, CFTR and TAP1. Thus, the three specific aims in this proposal will: (1) Test the hypothesis that Cif, by facilitating G3BP1 inhibition of USP10, reduces the deubiquitination of CFTR, thereby increasing the degradation of CFTR by lysosomes;(2) Test the hypothesis that Cif, by facilitating G3BP1 inhibition of USP10, inhibits the deubiquitination of TAP1, thereby targeting ubiquitinated TAP1 for degradation by the proteasome, and (3) Test the hypothesis that Cif, by reducing TAP1 levels, reduces MHC class I viral antigen presentation and cytotoxic T lymphocyte-mediated viral clearance. The studies proposed in this application will utilize a multi- disciplinary approach to examine host-pathogen interactions whereby the pathogen (P. aeruginosa) residing in the mucus layer overlying airway cells secretes a protein (Cif) that enters human airway epithelial cells and alters host immunity (i.e., mucociliary clearance and viral antigen presentation by MHC class I). Thus, the long- term goal of these studies is to elucidate how P. aeruginosa reduces the ability of the lung to clear infections and, ultimately, identify new therapeutic approaches to eliminate drug resistant P. aeruginosa infections.

Public Health Relevance

Bacterial infections affect ~2 million people in the US annually, result in ~99,000 deaths and require ~$4.5 billion/year in health care. Many of these infections are caused by the bacterium Pseudomonas aeruginosa. The long-term goal of our research is to understand how Pseudomonas aeruginosa causes lung infections and enhances viral infections, and to identify new therapeutic approaches to eliminate drug resistant Pseudomonas aeruginosa infections.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL074175-09
Application #
8513394
Study Section
Lung Cellular, Molecular, and Immunobiology Study Section (LCMI)
Program Officer
Banks-Schlegel, Susan P
Project Start
2003-08-15
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
9
Fiscal Year
2013
Total Cost
$374,660
Indirect Cost
$136,660
Name
Dartmouth College
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Seidler, Darius; Griffin, Mary; Nymon, Amanda et al. (2016) Throat Swabs and Sputum Culture as Predictors of P. aeruginosa or S. aureus Lung Colonization in Adult Cystic Fibrosis Patients. PLoS One 11:e0164232
Hogan, Deborah A; Willger, Sven D; Dolben, Emily L et al. (2016) Analysis of Lung Microbiota in Bronchoalveolar Lavage, Protected Brush and Sputum Samples from Subjects with Mild-To-Moderate Cystic Fibrosis Lung Disease. PLoS One 11:e0149998
Greene, Casey S; Foster, James A; Stanton, Bruce A et al. (2016) COMPUTATIONAL APPROACHES TO STUDY MICROBES AND MICROBIOMES. Pac Symp Biocomput 21:557-67
Hollomon, Jeffrey M; Grahl, Nora; Willger, Sven D et al. (2016) Global Role of Cyclic AMP Signaling in pH-Dependent Responses in Candida albicans. mSphere 1:
Bahl, Christopher D; Hvorecny, Kelli L; Bomberger, Jennifer M et al. (2015) Inhibiting an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa Protects CFTR. Angew Chem Int Ed Engl 54:9881-5
Notch, Emily G; Goodale, Britton C; Barnaby, Roxanna et al. (2015) Monomethylarsonous Acid (MMAIII) Has an Adverse Effect on the Innate Immune Response of Human Bronchial Epithelial Cells to Pseudomonas aeruginosa. PLoS One 10:e0142392
Moreau-Marquis, Sophie; Coutermarsh, Bonita; Stanton, Bruce A (2015) Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J Antimicrob Chemother 70:160-6
Heussler, Gary E; Cady, Kyle C; Koeppen, Katja et al. (2015) Clustered Regularly Interspaced Short Palindromic Repeat-Dependent, Biofilm-Specific Death of Pseudomonas aeruginosa Mediated by Increased Expression of Phage-Related Genes. MBio 6:e00129-15
Stanton, Bruce A; Coutermarsh, Bonita; Barnaby, Roxanna et al. (2015) Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells. PLoS One 10:e0127742
Thomas, Alissa A; Fisher, Jan L; Rahme, Gilbert J et al. (2015) Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol 17:801-9

Showing the most recent 10 out of 43 publications